Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17...
• Shareholders overwhelmingly vote in favour of Cybin’s acquisition of Small Pharma, supporting the combined company’s vision to build an international clinical-stage leader in psychedelic-based...
Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (“Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions and Cybin Inc. (NYSE...
• Shareholders overwhelmingly vote in favour of Cybin’s acquisition of Small Pharma LONDON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or...
LONDON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Mr. Peter Rands disposed of an aggregate of 1,532,001 common shares in the capital of Small Pharma Inc. (the “Company”) between September 25, 2023 and...
• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs • At Week 4, 100% of patients in the...
- Durch den Erwerb sämtlicher Aktien wird ein international führendes Unternehmen für neuartige psychedelische Therapeutika in der klinischen Phase geschaffen - - Es befinden sich zwei...
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics - - Two proprietary, advanced clinical programs in development for depression and anxiety...
• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an expedited route to an international, multi-site Phase II study with SPL028 in...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.15 | 0.15 | 0.15 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.15 | 0.15 | 0.15 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.15 | 0.15 | 0.15 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.15 | 0.15 | 0.15 | 0 | 0 | CS |
| 52 | 0 | 0 | 0.15 | 0.15 | 0.15 | 0 | 0 | CS |
| 156 | -0.09 | -37.5 | 0.24 | 0.395 | 0.06 | 119581 | 0.1355625 | CS |
| 260 | -0.85 | -85 | 1 | 1.1 | 0.06 | 117820 | 0.18554198 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
